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Xpert MtB/Rif ultra for rapid 
diagnosis of extrapulmonary 
tuberculosis in a high‑income 
low‑tuberculosis prevalence setting
ida Marie Hoel1, Heidi Syre2, ingerid Skarstein3 & tehmina Mustafa1,4*
the diagnosis of extrapulmonary tuberculosis (eptB) is often challenging due to paucibacillary 
nature of the disease. Xpert MtB/Rif Ultra (Ultra) has been developed to improve detection of 
Mycobacterium tuberculosis complex (Mtc) in paucibacillary specimens. the objective of the study 
was to assess the performance of Ultra for the diagnosis of eptB in a high‑income low tB prevalence 
country. extrapulmonary samples received for tB diagnostics at two hospitals in norway between 
January 2015 and January 2016 were prospectively and consecutively included. Defrosted samples 
were subjected to Ultra. Culture and routine PCR tests were used as reference standard. A total of 82 
samples, 10 culture and/or routine PCR positive (confirmed TB) samples and 72 culture and routine 
PCR negative samples were included in analysis. The overall sensitivity and specificity of Ultra were 
90% (9/10, 95% CI 56–100) and 99% (71/72, 95% CI 93–100), respectively. Ultra was positive in 6/7 
smear negative confirmed TB samples. To conclude, Ultra showed a high sensitivity and specificity in 
extrapulmonary specimens and may contribute to a rapid diagnosis of eptB in a low tB prevalence 
setting.
Tuberculosis (TB) is a global health  problem1. Extrapulmonary TB (EPTB) accounts for approximately 15% of 
notified TB cases  globally1, whereas as much as 40% of TB cases are extrapulmonary in several high-income 
countries, including  Norway1,2. Due to paucibacillary nature of the disease, the diagnosis of EPTB is often chal-
lenging. The worldwide roll-out in 2010 of the new PCR-based assay, Xpert MTB/RIF (Xpert; Cepheid, Sunny-
vale, CA), represented a breakthrough in TB  diagnostics3. The rapid and fully automated assay simultaneously 
detects Mycobacterium tuberculosis complex (MTC) species, the causative agents of TB, and rifampicin resistance 
(RIF-R), and has a high sensitivity for diagnosing pulmonary TB (PTB) in smear positive sputum  samples4. 
However, the sensitivity of Xpert in paucibacillary specimens, including smear negative PTB and many forms 
of EPTB, is  limited4–6. To improve the performance of Xpert in smear negative samples, an upgraded version 
of the assay, Xpert MTB/RIF Ultra (Ultra), has been  developed7. Ultra was launched in 2017 and is recom-
mended by the World Health Organization as a replacement for Xpert in all  settings8. The increased sensitivity 
of Ultra is achieved by incorporation of two new PCR assays targeting the multicopy genes IS6110 and IS1081 
for the diagnosis of TB, a larger DNA reaction chamber and transformation from hemi-nested to fully nested 
PCR  reactions7. A number of studies report increased sensitivity of Ultra compared to Xpert in smear negative 
 PTB9–16, and several studies also show promising results for diagnosing  EPTB11,14,15,17–25. However, most of the 
studies that investigate Ultra for diagnosing EPTB have been conducted in low-resource settings with high TB 
incidence. The aims of the present study were to (1) evaluate the diagnostic accuracy of Ultra for diagnosing 
EPTB compared to routinely used culture and PCR tests in a clinical setting in the high-income low TB preva-
lence country  Norway26, and (2) investigate the potential of Ultra as an add-on test to the existing routine tests 
to improve the rapid diagnosis of EPTB.
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Methods
Sample inclusion. The present study was performed on frozen specimens that had been collected as part of 
a larger prospective study conducted at Haukeland University Hospital, Bergen, Norway, between January 2015 
and June  201627. The study includes 47 specimens that were also included in the larger study, and 39 additional 
specimens that did not meet the inclusion criteria in the larger study. The eligibility criteria and reference stand-
ard were designed prior to Ultra testing. Samples eligible for inclusion were identified at the microbiology labo-
ratories at two regional tertiary care hospitals, Haukeland University hospital and Stavanger University hospital. 
All consecutive extrapulmonary samples received for TB diagnostics from patients of all ages were included 
during the study period, provided there was enough material left after routine diagnostics. As the diagnosis of 
EPTB almost always requires invasive sample collection, which is only performed on symptomatic patients with 
abnormal tissue masses or fluids, we assumed that the pre-test probability of TB was generally quite high in these 
samples. One exception was pleural fluid samples, which accounted for a large proportion of the samples, but 
often had a very low pre-test probability for TB because most of the samples were malignant pleural effusions 
routinely sent for TB diagnostics before initiation of cancer chemotherapy. Hence, pleural fluid samples were 
only included and subjected to Ultra if TB was mentioned as a probable differential diagnosis on the request 
form, whereas all other sample types were included without selection. Multiple samples were taken from some 
patients, and individual patients were allowed to contribute to the dataset multiple times. Results of routine 
TB diagnostic tests were obtained from the microbiology laboratory information systems. A microbiological 
reference standard was used in this study. Culture and/or routine PCR test positive samples were categorised as 
confirmed TB samples, and culture and routine PCR test negative samples were categorised as non-TB samples. 
Because information about clinical TB diagnosis was not available for all the samples in the cohort, we could 
not include a clinical TB diagnosis as part of the reference standard, and any sample included from a clinically 
diagnosed TB case was therefore categorised as a non-TB sample in this study.
Sample processing and routine tB diagnostic procedures. Laboratory personnel at the inclusion 
hospitals performed routine TB diagnostics according to local diagnostic algorithms. They were blinded to Ultra 
results. Fine needle aspirates (FNAs) and fluid samples with a volume of < 10 mL were used unconcentrated, 
whereas samples with a volume of > 10 mL were concentrated by centrifugation (3,800×g for 15 min) before 
resuspension of the sediment in saline. Biopsy specimens were mechanically homogenized and resuspended 
in saline. The Ziehl–Neelsen (ZN) method was used for detection of acid fast bacilli by smear microscopy. 
At Haukeland University hospital, a standard NALC-NaOH decontamination procedure was performed if the 
sample was assumed to be non-sterile, before seeding of appropriate sample volumes in liquid medium (BAC-
TEC MGIT) and solid medium (Lowenstein-Jensen containing glycerol and sodium pyruvate). All lymph node 
specimens, sterile fluids and aspirates and most biopsies were cultured both before and after NALC-NaOH 
decontamination, and lymph node specimens were also cultured at 28  °C. At Stavanger University hospital, 
most extrapulmonary samples were NALC-NaOH decontaminated and only cultured on liquid medium (Bactec 
MGIT 960; Becton Dickinson, Towson, MD). If the clinician requested PCR, appropriate sample volumes were 
further used for Cobas Taqman MTB (Roche, Switzerland), Abbott Real Time MTB (Abbot, Des Plaines, IL) or 
Genotype MTBDR plus (Hain Lifescience, Nehren, Germany), hereafter collectively referred to as routine PCR. 
Any remaining sample material was stored at − 80 °C for later analysis with Ultra.
Xpert ultra. We performed Xpert ultra on the frozen sample material during the autumn 2018, blinded for 
results of routine TB diagnostics and clinical information. Samples were thawed at room temperature and pro-
cessed according to the manufacturer’s protocol. All but two samples (both volume 0.25 mL) had a sample vol-
ume of minimum 0.5 mL. In samples with volume < 0.7 mL (n = 32), sample reagent was added in a 3:1 reagent 
to sample ratio, whereas a ratio of 2:1 was used for samples with a volume of 0.7 mL or more (n = 54).
Statistical analysis. Sensitivity, specificity and accuracy were calculated using culture and routine PCR as 
the reference standard. A minimum of one valid (positive or negative) culture result and a valid Ultra result were 
required to include a sample in this analysis. Calculation of 95% confidence intervals for sensitivity and specific-
ity was performed with the exact Clopper-Pearson method.
ethical considerations. The study was approved by the Regional Committee for Medical and Health 
Research Ethics of Western Norway (REK Vest), (2014/46/REK vest), and carried out in accordance with rel-
evant guidelines and regulations. REK Vest granted an exemption from informed consent from the patients, as 
the study only included residual material from samples sent for TB diagnostics in a clinical setting.
Results
Figure 1 provides the study overview. Frozen material was available from a total of 177 samples received for TB 
diagnostics during the study period, and comprised 21 biopsies, 16 lymph node FNAs, 16 pus samples and 124 
fluid samples. Pleural fluid samples accounted for more than half of all the specimens (n = 109), but TB was only 
mentioned as a probable differential diagnosis on the request form for 18/109 samples. We excluded the 91 pleural 
fluids with assumed low pre-test probability of TB and analysed the remaining 86 extrapulmonary samples (from 
80 cases) with Ultra. All these samples had a minimum of one valid culture result (positive or negative) available. 
Four samples were excluded from further analysis due to invalid Ultra result (ERROR).
The type and number of routine TB diagnostic tests performed on the analysed samples varied (Table 1). All 
samples were subjected to culture, 85% to ZN microscopy (n = 70) and 24% to a routine PCR (n = 20). MTC was 
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detected in ten samples (positive culture and/or routine PCR), hereafter called confirmed TB samples, while 72 
samples were culture and routine PCR negative (Table 1). HIV status was unknown for all cases.
test performance of ultra compared to routine tB diagnostic tests. Using culture and/or routine 
PCR as reference standard, Ultra was positive in 9 of 10 confirmed TB samples, giving an overall sensitivity 
of 90% (95% CI 56–100) (Table 2). Among the nine culture positive TB samples, Ultra was positive in eight 
(Fig. 2). All the smear positive (3/3) and 6/7 (86%) smear negative confirmed TB samples were Ultra positive. 
Semi-quantitation of bacillary load by Ultra categorised the TB samples as medium (n = 3), low (n = 3), very 
low (n = 1) and trace (n = 2). None of the TB samples had a high bacillary load. Among the 8 culture and Ultra 
positive samples, genotypic RIF-R was detected by Ultra in two samples, not detected in four samples and inde-
terminate in the two samples semi-quantitated as “trace”. The genotypic RIF-R results were in concordance with 
the phenotypic drug susceptibility test (DST) results. The two samples with indeterminate RIF-R by Ultra were 
both sensitive to first line TB drugs in phenotypic DST.
One of the 72 culture and routine PCR negative samples was Ultra positive, yielding an overall specificity of 
99% (95% CI 93–100) for Ultra. This sample was a lymph node biopsy from a patient with lymphadenitis fol-
lowing BCG vaccination. The lymphadenitis healed spontaneously and was eventually interpreted as an immune 
reaction to the vaccine. Among the culture and routine PCR negative samples were also three non-tuberculous 
mycobacteria (NTM) culture positive samples, identified as Mycobacterium avium. All three were Ultra negative.
Discussion
In the present study we have investigated the performance of Ultra compared to routine TB diagnostic tests for 
diagnosing EPTB in a small cohort of prospectively collected extrapulmonary specimens in a high resource set-
ting with a low TB prevalence. Using culture and/or routine PCR as reference standard, we found that Ultra had 
an overall sensitivity and specificity of 90% (95% CI 56–100) and 99% (95% CI 93–100), respectively. In smear 
negative confirmed TB samples, the sensitivity of Ultra was 86% (95% CI 42–100).
Several studies have been published on the diagnostic accuracy of Ultra in extrapulmonary 
 specimens11,14,15,17–25,28,29. Most of the studies were performed in TB endemic  settings14,17,19–25,28,29, and only three 
studies have investigated Ultra test performance in low TB prevalence  settings11,15,18. However, two of these stud-
ies were retrospective and performed on selected sample material. A strength of our study is that it is a prospec-
tive cohort study with consecutive inclusion of samples in a clinical routine setting, and the study population 
is thus more likely to be representative of the true test population in a low TB prevalence setting. The majority 
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Figure 1.  Overview of study design. The type of routine PCR test performed varied between the inclusion 
hospitals, and included Cobas Taqman MTB (Roche, Switzerland), Abbott Real Time MTB (Abbot, Des Plaines, 
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of extrapulmonary samples tested for TB in Norway are from patients with other diseases than TB. Hence, it 
may be just as important to avoid false positive test results in the large group of non-TB cases, which can lead to 
overtreatment and potentially severe side effects, as to obtain a more rapid TB diagnosis in the small group of 
TB cases. Our study can provide useful information about test performance in these clinically relevant non-TB 
cases, which we think is of particular importance in our setting. Indeed, the specificity of Ultra in our study was 
Table 1.  Distribution of routine TB diagnostic tests performed and results of routine TB diagnostic tests and 
Xpert MTB/RIF Ultra. HUH Haukeland University Hospital, SUH Stavanger University Hospital. a Two of the 
samples (culture positive biopsy and culture positive fluid sample) are from the same TB case. b Includes three 
samples from clinically diagnosed TB cases (one pus sample, one biopsy and one lymph node aspirate). c The 
two microscopy positive samples were both culture positive for Mycobacterium avium. d Microscopy positive 
sample was culture positive for Mycobacterium avium. e Five culture negative biopsy samples were subjected to 
routine PCR, of which one PCR test result was indeterminate (technical failure). The indeterminate PCR result 
has been excluded from the results and analysis.
Culture and/or PCR positive  samplesa Number of samples
Routine TB diagnostic tests (positive/
total number)
Xpert UltraMicroscopy Routine PCR Culture
Lymph node biopsy 1 0/1 1/1 1/1 1/1
Lymph node aspirate 4 3/4 3/3 4/4 4/4
Pus samples 2 0/2 2/2 1/2 2/2
Other biopsies (pleura) 1 0/1 0/1 1/1 1/1
Fluid samples 1 0/1 0/1 1/1 0/1
Gastrointestinal lavage 1 0/1 1/1 1/1 1/1
Total 10 3/10 7/9 9/10 9/10
Samples per inclusion site
Samples from HUH 8 3/8 5/7 8/8 7/8
Samples from SUH 2 0/2 2/2 1/2 2/2
Culture and PCR negative samplesb
Lymph node biopsy 4 1/4 0/1 0/4 1/4
Lymph node aspirate 11 2/11c 0/3 0/11 0/11
Pus samples 14 1/14d 0/1 0/14 0/14
Other biopsies 13 0/13 0/4e 0/13 0/13
Fluid samples 28 0/17 0/3 0/28 0/28
Gastrointestinal lavage 2 0/1 N/A 0/2 0/2
Total 72 4/60 0/12 0/72 1/72
Samples per inclusion site
Samples from HUH 58 3/53 0/9 0/58 0/58
Samples from SUH 14 1/7 0/3 0/14 1/14
Table 2.  Validation of Xpert MTB/RIF Ultra using culture and/or routine PCR tests as a reference standard. 
95% confidence intervals for sensitivity, specificity and accuracy were calculated using the exact Clopper–
Pearson method. CI confidence interval, TP true positive, FN false negative, TN true negative, FP false positive.
Sample material
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high (99%). This is in concordance with the specificities (97–100%) found in other low TB prevalent settings 
where culture was used as reference  standard15,18. However, in most of the studies that directly compare the 
performance of Xpert and Ultra, the specificity of Ultra is reduced compared to Xpert, both in extrapulmonary 
 specimens14,19,20,22,29 and  sputum9,10,12,13. In low TB prevalent settings, even a small reduction in specificity could 
lead to unacceptable high rates of false positive cases, emphasizing that Ultra should be performed on selected 
samples with a high pre-test probability of TB disease.
Only one culture and routine PCR negative sample in our cohort was Ultra positive (“trace”). The sample came 
from a patient with regional lymphadenitis following BCG vaccination. As the BCG strains are also members 
of the  MTC30,31, the Ultra result may have been true positive for this case. However, Ultra is not able to separate 
non-viable from viable bacilli and cannot provide information as to whether the DNA present in the sample 
represented active mycobacterial disease or remnants of old DNA from the vaccine. This illustrates the challenges 
in interpreting positive Ultra results in certain clinical contexts. The inability of Ultra to separate viable from 
non-viable bacilli also limits its use for detection of relapse and reinfection. Dorman and colleagues reported 
a reduced specificity of Ultra in previously treated TB patients up to seven years after completion of treatment 
compared to patients with no previous history of  TB9. This underlines the importance of culture for TB diagnosis.
Most, but not  all28,29, of the studies that investigate Ultra for the diagnosis of EPTB suggest increased sensi-
tivity of Ultra compared to Xpert in different extrapulmonary  specimens11,14,15,17,19–23,25. When culture is used 
as reference standard, the reported sensitivity of Ultra varies, but is generally high in lymph node specimens 
(90–94%)18,24, FNAs and tissue samples (87–95%)18,22, cerebrospinal fluid (80–100%)17,18,21,25,29 and pus specimens 
(65–95%)18,19, and lower in pleural fluid samples (48–84%)18,20,22,23, which is in line with our findings. Several 
of the studies also show that Ultra can detect MTC in culture negative specimens from clinically diagnosed TB 
 cases17,19–25,28,29, thus, contributing to improved diagnosis of TB in samples with a very low bacillary load.
The ability of Xpert and Ultra to simultaneously detect MTC and RIF-R is considered one of the strengths 
of the assays. In addition to detection of the single-copy rpoB gene for the simultaneous diagnosis of TB and 
rifampicin resistance, Ultra includes two new and more sensitive PCR assays that target the multicopy IS6110 
and IS1081 genes to improve MTC detection in paucibacillary  samples7. However, the increased sensitivity of the 
test comes with an expense, because information about RIF-R is not available in IS6110 or IS1081 positive and 
rpoB negative samples, which are categorised as “trace” by  Ultra7,18. Two of the culture confirmed TB samples in 
our study were Ultra “trace” positive. For these samples, information about drug resistance was only provided by 
culture, and both were drug sensitive. The incidence of multidrug resistant (MDR)-TB is low in our  setting26, but 
in high MDR-TB incidence settings, MDR-TB cases can be missed among the “trace” positive samples. Therefore, 
Ultra should complement, but not replace culture.
This study has some limitations. The small sample number leads to uncertain sensitivity estimates. The study 
was performed in a clinical routine setting, and the combination of routine TB diagnostics used and sample 
processing varied slightly between the inclusion hospitals. The number of cultures performed per sample and the 
use of decontaminated versus not-decontaminated material may affect the sensitivity of culture. At both inclusion 
sites, fluid samples and FNAs with a volume of > 10 mL were concentrated before use. Hence, we cannot evaluate 
the overall effect of sample concentration on Ultra test performance, as some samples were concentrated and 
others were not. The use of frozen sample material for Ultra may also affect the performance of the assay due to 
reduced sample quality. However, studies that have specifically investigated the Xpert/Ultra test performance 
on frozen samples report discordant results, but the effect is small in the studies that find a  difference6,12,18,32. 
Furthermore, DNA remains quite stable under frozen conditions, and our samples were only subjected to one 
freeze–thaw cycle. These findings imply that the impact of frozen samples on Ultra performance is small. Larger 
and more controlled studies with uniform sample processing should be conducted to adjust for these limitations. 
As culture is known to be an imperfect reference standard in paucibacillary cases of EPTB, future studies should 
focus on diagnostic accuracy of TB diagnostic tests both in microbiologically confirmed and clinically diagnosed 
TB subjects to better reflect the true test performance in all clinically relevant groups of the test population.
To conclude, the sensitivity and specificity of Ultra was comparable to culture in most sample materials in this 
study with the advantage of results within hours. These promising findings suggest that Ultra is a useful add-on 
test that can contribute to a rapid diagnosis of EPTB in our setting. However, the inability of Ultra to separate 
viable from non-viable bacilli and the lack of information about drug resistance for “trace” positive samples, 
limits its use in some clinical cases, especially in patients previously treated for TB.
Figure 2.  Euler diagram illustrating overlap of positive results of routine TB diagnostic tests and Xpert MTB/
RIF Ultra in confirmed TB samples (n = 10).
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Data availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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